Brief: Revive Therapeutics Expands Bucillamine Research To Treat Omicron Variant And Adds Inflammatory Markers To FDA Phase 3 Clinical Trial
03/12/2021 13:36
Dec 3 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS EXPANDS BUCILLAMINE RESEARCH TO TREAT
OMICRON VARIANT AND ADDS INFLAMMATORY MARKERS TO FDA PHASE 3
CLINICAL TRIAL
Source text for Eikon: ID:nGNX9gX12Z
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure